{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:23:20Z","timestamp":1787671400390,"version":"build-2736575974"},"reference-count":32,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney Dis"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Background: This study aimed to describe disease activity, clinical outcome, and overall patterns of lupus nephritis care in patients who received belimumab in a real-world clinical setting in China. Materials and Methods: This observational cohort study included lupus nephritis patients who received belimumab as adjunct therapy. We deeply investigated the characteristics of those patients including clinical response to belimumab and safety. Results: All 61 lupus nephritis patients were included with a median follow-up period of 9 months (6, 19). Prevalence of proteinuria (52.5\u201324.6%) and hematuria (33.3\u20139.8%) was decreased with a stable level of eGFR at last visit. The percentage of patients achieved complete or partial renal response increased from 47.5% to 78.7% and the proportion of complete or partial renal response in patients with proliferative lupus nephritis was higher than those with membranous lupus nephritis (75 vs. 50%) at last visit. The median SLEDAI score decreased from 6 to 2, and there was an increase in patient of LLDAS from 17 to 33 at last visit. A notable dose reduction was seen for glucocorticosteroid dose, with a median change from 10 to 5 mg\/d. The proportion of patients receiving &amp;gt;7.5 mg\/d steroids reduced from 52.5% at baseline to 23.0% at last visit. The discontinuation of belimumab was rare (3\/61) for drug-induced fever, hyperthyroidism, and uveitis. Conclusions: Lupus nephritis patients with belimumab demonstrated improvements in clinical response and a reduction in glucocorticosteroids, which provided evidence of effectiveness and safety in real-world clinical practice in China. <\/jats:p>","DOI":"10.1159\/000529675","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T22:00:50Z","timestamp":1676412050000},"page":"218-228","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China"],"prefix":"10.1159","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1532-7922","authenticated-orcid":false,"given":"Meng","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-5758","authenticated-orcid":false,"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9492-1078","authenticated-orcid":false,"given":"Zhen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.02.014"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/1574887112666171123113200"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs073"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.050600"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0807841105"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.21138"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000118"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0047-x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3682-9"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2019.20022"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.41253"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312465781"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102729"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.136"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2017.01.005"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes218"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8675-2"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.027"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8%3c1801::AID-ANR16%3e3.0.CO;2-O"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"}],"container-title":["Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/kdd\/article-pdf\/9\/3\/218\/3959043\/000529675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/kdd\/article-pdf\/9\/3\/218\/3959043\/000529675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:15:53Z","timestamp":1745421353000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000529675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,30]]}},"URL":"https:\/\/doi.org\/10.1159\/000529675","archive":["Portico"],"relation":{},"ISSN":["2296-9381","2296-9357"],"issn-type":[{"value":"2296-9381","type":"print"},{"value":"2296-9357","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}